Stock Analysis

Is It Too Late To Consider Buying Teladoc Health, Inc. (NYSE:TDOC)?

NYSE:TDOC
Source: Shutterstock

Teladoc Health, Inc. (NYSE:TDOC), might not be a large cap stock, but it saw significant share price movement during recent months on the NYSE, rising to highs of US$33.20 and falling to the lows of US$22.29. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Teladoc Health's current trading price of US$24.08 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Teladoc Health’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for Teladoc Health

Is Teladoc Health Still Cheap?

Great news for investors – Teladoc Health is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $33.37, but it is currently trading at US$24.08 on the share market, meaning that there is still an opportunity to buy now. What’s more interesting is that, Teladoc Health’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

Can we expect growth from Teladoc Health?

earnings-and-revenue-growth
NYSE:TDOC Earnings and Revenue Growth March 10th 2023

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Teladoc Health's earnings over the next few years are expected to increase by 99%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? Since TDOC is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on TDOC for a while, now might be the time to enter the stock. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy TDOC. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed buy.

So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For example, we've discovered 2 warning signs that you should run your eye over to get a better picture of Teladoc Health.

If you are no longer interested in Teladoc Health, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Valuation is complex, but we're here to simplify it.

Discover if Teladoc Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.